Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Bluebird Bio Inc (BLUE) USD0.01

Sell:$29.33 Buy:$29.38 Change: $1.46 (4.74%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
Sell:$29.33
Buy:$29.38
Change: $1.46 (4.74%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
Sell:$29.33
Buy:$29.38
Change: $1.46 (4.74%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Contact details

Address:
60 Binney St
CAMBRIDGE
02142-1512
United States
Telephone:
+1 (339) 4999300
Website:
www.bluebirdbio.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BLUE
ISIN:
US09609G1004
Market cap:
$2.02 billion
Shares in issue:
67.14 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Daniel Lynch
    Independent Chairman of the Board
  • Nick Leschly
    President, Chief Executive Officer, Director
  • William Baird
    Chief and Principal Financial Officer, Interim Principal Accounting Officer
  • Jason Cole
    Chief Operating Officer and Legal Officer, Secretary
  • Philip Gregory
    Chief Scientific Officer
  • David Davidson
    Chief Medical Officer
  • Alison Finger
    Chief Commercial Officer
  • Joanne Smith-Farrell
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.